NOX 1.52% 6.7¢ noxopharm limited

Ann: Positive DARRT-1 Data in Late-Stage Prostate Cancer, page-23

  1. 85 Posts.
    lightbulb Created with Sketch. 92
    This release isn’t really accurate. The tumour response rate isn’t 66%. Only one of the 15 evaluable actually had a response (partial) so the tumour response rate is 6.6%. Stable disease isn’t considered “responder” by accepted oncology criteria.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.